NCT06698757View on ClinicalTrials.gov

Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

November 15, 2024

Primary Completion Date

November 15, 2027

Study Completion Date

November 15, 2031

Conditions
Colorectal Cancer
Interventions
BIOLOGICAL

Sintilimab

Subjects were enrolled and received Sintilimab at a dose of 200 mg, administered via intravenous infusion on the first day of each cycle, with each cycle lasting 3 weeks (Q3W)

Trial Locations (1)

450000

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zheng'zhou

All Listed Sponsors
lead

Yugui Lian

OTHER